Radiopharmaceuticals May Be Eligible For ASP Reimbursement Under CMS Proposal
This article was originally published in The Pink Sheet Daily
Executive Summary
Two key drugs likely to be affected by such a change are Cell Therapeutics’ Zevalin and GlaxoSmithKline’s Bexxar.
You may also be interested in...
Zevalin On Track For Medicare ASP-Based Reimbursement In 2010
Change to average sales price based payment for Cell Therapeutics’ radioimmunotherapy could help boost use in community oncology centers.
Zevalin On Track For Medicare ASP-Based Reimbursement In 2010
Change to average sales price based payment for Cell Therapeutics’ radioimmunotherapy could help boost use in community oncology centers.
Congress Overrides Bush’s Medicare Veto
Doctors’ reimbursement cut is quashed; radioimmunotherapies gain special benefit.